Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.
复制标题
DOI：
10.1016/j.cpet.2018.02.010
复制
发表时间：
2018-07
期刊：
影响因子：
2.6
通讯作者：
Lewis JS
中科院分区：
文献类型：
--
作者：
Henry KE;Ulaner GA;Lewis JS
HER蛋白家族的表达增加，特别是HER2和HER3，是乳腺癌中的生物标志物，已成为分子成像和治疗的重要靶点。靶向HER2和HER3的成像方式能够以非侵入性方式诊断具有特定生物学相关靶标的乳腺癌。重复的肿瘤活检不能解决肿瘤内或原发病和转移之间的异质性问题。HER2和HER3靶向PET是诊断乳腺癌疾病状态和评估靶向这些受体治疗反应的重要工具。PET是一种具有亚纳摩尔检测的高灵敏度和定量成像技术。放射性标记生物分子的PET和SPECT可用于非侵入性检测和特定靶点的定量，使医生和科学家能够更好地了解患者队列的治疗行为和有效性。
Increased expression of the HER protein family, especially HER2 and HER3, are biomarkers in breast cancer that have become significant targets for molecular imaging and therapy. Imaging modalities that target HER2 and HER3 have the ability to diagnose breast cancer with a specific, biologically relevant target in a non-invasive manner. Repeat tumor biopsies do not address the issue of heterogeneity intratumorally or between primary disease and metastasis. HER2- and HER3- targeted PET is an important tool to diagnose disease state in breast cancer and evaluate response to therapies that target these receptors. PET is a highly sensitive and quantitative imaging technique with subnanomolar detection. PET and SPECT with radiolabeled biomolecules can be used for noninvasive detection and quantification of specific targets, allowing physicians and scientists alike to better understand the behavior and effectiveness of treatment across patient cohorts.